Despite the disappointing result,
@MsStat2 had so many positives. Remaining active during the pandemic, often being the only contact people with MS had with HCP’s to name but one.
Onwards and upwards now with OCTOPUS!🐙
Today the results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen.
This trial tested simvastatin, commonly used to treat high cholesterol, in 964 people with secondary progressive MS. (1/6)